MAPT and Cognitive impairment: These endpoints include measures of pathological tau, tau‐modifying enzymes, brain volume/neuronal loss, synaptic degeneration, synaptic dysfunction, neuroimmune response, autophagy/UPS‐mediated degradation of tau, cognitive deficits, behavioral and psychological symptoms of dementia (BPSD)/ADL, motor deficits, survival, and treatment response biomarkers (Figure 6A).